Patrick Machado Joins ACELYRIN Board of Directors

ACELYRIN, Inc., is a biopharma company based in Los Angeles, California. It has focused on delivering critical patients with life-changing new experiences and innovative treatment options by identifying, acquiring research data, and bolstering the development and commercialization of potential drug candidates with promising results. ACELYRIN announced the addition of Patrick Machado, JD, to the company’s board of directors on Thursday, June 10. Mr. Machado has a very impressive and strengthening portfolio with over two decades of experience in core biopharmaceutical organizations, helping them grow and develop via commercialization.

Machado also has substantial experience of operational significance, with responsibilities such as leading finance, business development, and legal functions for many companies. Shao-Lee Lin, MD, Ph.D., co-founder and chief executive officer of ACELYRIN, welcomed Patrick Machado and stated that his insights would be valuable in pursuing the singular goal of pushing ACELYRIN to become new life-changing medicines.

Machado presently acquires that seat at the table of board members of Adverum Biotechnologies Inc., along with Chimerix Inc., Turning Point Therapeutics. He also serves on the board of Roivant Sciences Ltd., Xenon Pharmaceuticals along with Turnstone Biologics, and Arcus Biosciences. He has also served as director of Endocyte prior to the acquisition led by Novartis.

The broad spectrum of expertise acquired by Mr. Machado includes executive management, mergers & acquisitions, negotiations conducted during joint ventures, equity investment knowledge, licensing of technology, initiating R&D agreements, and reimbursements from health plans. Prior to this, Machado worked at Morrison and Foerster LLP as an attorney in the corporate finance department before the onset of his highly successful biotech journey.